The APTX Knockout A-549 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal cell population originating from the A-549 human lung adenocarcinoma epithelial line. Disruption of the APTX gene, which encodes the DNA repair enzyme aprataxin, is achieved through a CRISPR/Cas9-mediated gene-editing strategy, yielding a loss-of-function model. The polyclonal nature preserves the inherent genetic diversity of the edited pool, making it suitable for experiments where clonal variability is minimized and the functional consequences of gene disruption are assessed across a heterogeneous cell population.
The A-549 host cell line, derived from a 58-year-old Caucasian male with lung adenocarcinoma, is a classic model for respiratory epithelial biology and drug metabolism studies. These cells express a KRAS G12S oncogenic variant and retain wild-type p53, allowing integrated analysis of oncogenic signaling and DNA damage response pathways. Their robust proliferation and well-characterized phenotype underpin their widespread use in cancer research, including investigations of DNA repair and therapeutic resistance.
Aprataxin resolves abortive DNA ligation intermediates by removing 5??-AMP adducts during single-strand break repair (SSBR) and base excision repair (BER). It forms complexes with XRCC1, DNA ligase III, PARP1, and PNKP. Its activity is regulated by the DNA damage-responsive kinases ATM and ATR, and its loss leads to accumulation of oxidative lesions and genome instability. Mutations in APTX cause ataxia with oculomotor apraxia type 1 (AOA1), a neurodegenerative disorder.
In A-549 adenocarcinoma cells, APTX knockout allows dissection of DNA repair dependencies in a KRAS-mutant, p53-wild-type background. This model is particularly suited for PARP inhibitor synthetic lethality studies, as aprataxin loss is expected to sensitize cells to agents that generate DNA lesions requiring its processing. It also enables comparative analyses between proliferating cancer cells and post-mitotic neurons affected in AOA1 neurology.
Applications include monitoring DNA damage via ??H2AX immunofluorescence and comet assay, confirming gene disruption by western blot and RT-qPCR, and assessing cell survival after MMS or PARP inhibitor exposure using clonogenic assays. This polyclonal knockout tool supports research in DNA repair, lung cancer vulnerabilities, and AOA1 neurodegeneration. Contact Ascent Research for ordering information.
